Compare › dulaglutide vs semaglutide
dulaglutide vs semaglutide
Both dulaglutide and semaglutide are approved in the US, so the useful differences between them are which conditions each is approved for and what is still under study. dulaglutide has 66 trials on file here and semaglutide 429, which is a rough measure of how far each programme has been pushed.
A side-by-side of what the public record holds on each: regulatory status in the US and EU, how much trial work is running, and which conditions each is being studied in. No efficacy comparison: head-to-head claims belong to the trials that made them, not to us.
| dulaglutide | semaglutide | |
|---|---|---|
| Status | marketed | marketed |
| Target | GLP-1 | GLP-1 |
| Route | SC | SC/oral |
| Sponsor | Eli Lilly | Novo Nordisk |
| US brand names | TRULICITY | OZEMPIC, RYBELSUS, WEGOVY, WEGOVY FLEXTOUCH, WEGOVY HD |
| First FDA approval | 2014-09-18 | 2017-12-05 |
| EU authorisation | Trulicity | Ozempic, Rybelsus, Wegovy |
| FDA actions on file | 22 | 52 |
| Active trials | 11 | 214 |
| Active phase 3 | 5 | 75 |
| Participants enrolled | 2,694 | 98,857 |
| Results scheduled | 3 | 96 |
| Supply records | 0 | 3 |
Where they are being studied
Both: Cardiovascular disease; Chronic kidney disease; Diabetes (unspecified); Diabetic kidney disease; MASH / NAFLD; Obesity & overweight; Polycystic ovary syndrome; Substance use; Type 1 diabetes; Type 2 diabetes
semaglutide only: Alcohol use disorder; Atrial fibrillation; Cancer; Heart failure; Hypertension; Metabolic syndrome; Neurodegenerative disease; Obstructive sleep apnea; Prediabetes; Psychiatric conditions